Encoded Therapeutics is a clinical stage biotech developing precision genetic medicines through a proprietary vector engineering platform that enables cell type selective gene expression control in the brain and peripheral nervous system. Its lead program ETX101 is an AAV gene therapy for SCN1A-positive Dravet syndrome.